New study reveals how local surgery affects bowel and bladder function after rectal cancer treatment
NCT ID NCT06249672
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 200 adults with rectal cancer who had chemoradiotherapy and then chose organ-preserving treatment. Some had a small local surgery to remove the scar, while others did not. Researchers will compare bowel, bladder, and sexual function between the two groups over the long term to help patients and doctors make better treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients treated for rectal cancer at Bern University hospital have to be discussed in the colorectal MDT per institutional guidelines. In order to identify all eligible patients, MDT lists are screened weekly and all patients meeting in-/exclusion criteria asked for consent. If consent is given, participants will be included.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \>18 years of age * Informed consent * Diagnosis of rectal cancer, \<12cm from anal verge * Treatment by chemoradiation (short course 5x5 Gy or 28x1.8 Gy with concomitant 5FU) * Re staging with MRI/endoscopy shows (near) complete response (max 2cm tumor scar) * Decision for treatment by organ preservation strategy (with or without local excision) Exclusion Criteria: * Inability to give consent * Follow-up not possible
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Bern University Hospital, Inselspital
RECRUITINGBern, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
- Can digital surveys capture the full toll of rectal cancer treatment?
- Can a targeted drug conjugate outsmart advanced colorectal cancer?
- Can a platform trial match the right drug combo to each tumor?
- Laser light may help surgeons spot risky bowel connections